Inclusion Criteria:

          -  Diagnosis of histologically or cytologically confirmed metastatic adenocarcinoma of
             the colon or rectum.

               -  Primary tumor has been resected > 3 months prior to randomization.

          -  At least 1 lesion on a computed tomography (CT) scan (preferred) or magnetic resonance
             imaging (MRI) that is measurable as defined by Response Evaluation Criteria In Solid
             Tumors (RECIST), Version 1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.

          -  Progression following treatment with fluoropyrimidine/oxaliplatin/bevacizumab-regimen
             in the metastatic setting.

          -  Adequate hematologic, renal and hepatic function.

        Exclusion Criteria:

          -  Any prior therapy with irinotecan

          -  Unresolved clinically significant toxicities from prior anticancer therapy, defined as
             any Common Terminology Criteria for Adverse Events (CTCAE) => Grade 2

          -  Clinically significant conditions that increase the risk for antiangiogenic therapy.

          -  History of any of the following during first-line therapy with a
             bevacizumab-containing regimen: arterial thrombotic/thromboembolic event, bowel
             perforation, Grade 4 hypertension, Grade 3 proteinuria or Grade 3 - 4 bleeding event.